Adlai Nortye Ltd. (ANL:NASDAQ) closed at $10.59 on October 20, 2026, up 2.02% on the day. The stock trades 38.6% below its 52-week high of $17.25 and 1,104.8% above its 52-week low of $0.879. Over the past year, it gained 529.1%. Adlai Nortye Ltd. is part of the Health Care sector.
In 252 trading sessions since October 17, 2025, ANL closed higher on 129 days (51%). Its best day was January 29, 2026 (+88.18%) and its worst was October 13, 2026 (-17.33%). The stock moved 10% or more in a single session 33 times. It opened at least 5% above the previous day's high 2 times.
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company's pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
Find more stocks like ANL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.